June 3, 2020 / 12:49 PM / a month ago

BRIEF-Aprea Completes Full Enrollment Of Phase 3 Clinical Trial In Tp53 Mutant Myelodysplastic Syndromes

June 3 (Reuters) - Aprea Therapeutics Inc:

* APREA THERAPEUTICS COMPLETES FULL ENROLLMENT OF PHASE 3 CLINICAL TRIAL IN TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS)

* APREA THERAPEUTICS INC - TOPLINE RESULTS ARE EXPECTED BY YEAR-END 2020

* APREA THERAPEUTICS INC - PLANS TO INCLUDE RESULTS OF TRIAL IN A NDA TO FDA, MARKETING AUTHORIZATION APPLICATION TO EMA IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below